Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keyur Patel

Showing results (331-340 of 357) with videos related to

Pageof 36
Sort By:
The New England Journal of Medicine|April 24, 2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsIra M Jacobson, Stuart C Gordon, Kris V Kowdley, et al.
American Journal of Hematology|November 6, 2020
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Veronica Guerra, et al.
Blood|December 23, 2016
Long-term outcome of acute promyelocytic leukemia treated with all-<i>trans</i>-retinoic acid, arsenic trioxide, and gemtuzumabYasmin Abaza, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Leukemia|May 19, 2021
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrationsNitin Jain, Philip Thompson, Jan Burger, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 14, 2021
Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology GroupRashmi Kanagal-Shamanna, Attilio Orazi, Robert P Hasserjian, et al.
Haematologica|December 12, 2024
Clinical interrogation of <i>TP53</i> aberrations and its impact on survival in patients with myeloid neoplasmsJayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, et al.
American Journal of Hematology|March 1, 2020
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapyGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Caleb A Class, et al.
The Lancet. Haematology|November 19, 2022
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trialElias Jabbour, Nicholas J Short, Nitin Jain, et al.
Cardiology and Therapy|November 6, 2024
Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in IndiaUday M Jadhav, Saumitra Ray, T Govindan Unni, et al.
Pageof 36

Showing results (331-340 of 357) with videos related to

Sort By:
Pageof 36
The New England Journal of Medicine|April 24, 2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsIra M Jacobson, Stuart C Gordon, Kris V Kowdley, et al.
American Journal of Hematology|November 6, 2020
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Veronica Guerra, et al.
Blood|December 23, 2016
Long-term outcome of acute promyelocytic leukemia treated with all-<i>trans</i>-retinoic acid, arsenic trioxide, and gemtuzumabYasmin Abaza, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Leukemia|May 19, 2021
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrationsNitin Jain, Philip Thompson, Jan Burger, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 14, 2021
Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology GroupRashmi Kanagal-Shamanna, Attilio Orazi, Robert P Hasserjian, et al.
Haematologica|December 12, 2024
Clinical interrogation of <i>TP53</i> aberrations and its impact on survival in patients with myeloid neoplasmsJayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, et al.
American Journal of Hematology|March 1, 2020
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapyGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Caleb A Class, et al.
The Lancet. Haematology|November 19, 2022
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trialElias Jabbour, Nicholas J Short, Nitin Jain, et al.
Cardiology and Therapy|November 6, 2024
Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in IndiaUday M Jadhav, Saumitra Ray, T Govindan Unni, et al.
Pageof 36